Survival and Quality of Life Over a Decade After Pelvic Exenteration

Overview

This longitudinal study of 273 patients undergoing pelvic exenteration found that one-third survived beyond 10 years, with median overall survival of 4.8 years. Quality-of-life assessments demonstrated sustained improvements, with mental and physical health scores approaching or maintaining population norms over long-term follow-up.

Background

Pelvic exenteration is a radical surgical procedure offering potential cure for advanced or recurrent pelvic malignancies but is associated with significant morbidity and impact on quality of life. While 5-year survival rates vary widely, long-term data beyond 5 years are scarce, especially regarding patient-reported outcomes. Understanding survival and quality-of-life trajectories beyond 10 years is critical to inform treatment decisions and patient counseling.

Data Highlights

Key Findings

• One-third of patients survived beyond 10 years after pelvic exenteration.
• Median overall survival was 4.8 years, with 5-, 10-, and 15-year survival rates of 48.4%, 35.1%, and 31.5%, respectively.
• Quality of life, measured by FACT-C scores, improved steadily over the first 18 months post-surgery and was maintained thereafter.
• Mental health scores (SF-36v2 Mental Component Summary) approached population norms after initial improvement.
• Physical health scores (SF-36v2 Physical Component Summary) remained stable and within population norms throughout follow-up.
• Long-term quality-of-life outcomes support pelvic exenteration as a curative option for selected patients despite the procedure's morbidity.

Clinical Implications

Pelvic exenteration offers promising long-term survival for selected patients with advanced pelvic cancers, with a substantial proportion surviving beyond 10 years. Clinicians can counsel patients that quality of life typically improves within 18 months postoperatively and remains stable long-term, with mental and physical health comparable to general population norms. These findings support the use of pelvic exenteration as a curative treatment in specialized centers with multidisciplinary care.

Conclusion

Pelvic exenteration provides durable survival benefits and sustained quality-of-life improvements beyond a decade post-surgery. These results reinforce its role as a viable curative option for carefully selected patients with advanced pelvic malignancies.

References

1. Original Article 2024 -- Survival Rates and Quality of Life Assessment in Patients Over a Decade Post-Pelvic Exenteration